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Abstract: Very low-calorie diets (VLCD) are hypocaloric dietary regimens of approximately
400–800 kcal/day that result in 20–30% reductions in body weight, sometimes in just 12–16 weeks.
A body of evidence demonstrates that adherence to VLCD in adults with type 2 diabetes (T2D) can
result in marked improvements to glycemic control and even full T2D remission, challenging the
convention that T2D is a lifelong disease. Although these data are promising, the majority of VLCD
studies have focused on weight loss and not T2D remission as a primary endpoint. Moreover, there
is a wide range of VLCD protocols and definitions of T2D remission used across these hypocaloric
studies. Together the large degree of heterogeneity in VLCD studies, and how T2D remission is
defined, leave many gaps in knowledge to efficacy and durability of VLCD approaches for T2D
remission. This narrative review examines findings from a body of data from VLCD studies that
specifically sought to investigate T2D remission, and discusses the efficacy of VLCD compared to
other hypocaloric approaches, and who is likely to benefit from VLCD approaches for T2D remission.
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1. Introduction

Sergio Martínez-Hervás and

Type 2 diabetes (T2D) and its comorbidities have reached epidemic proportions
globally [1], largely driven by high rates of obesity in adults and children. With less than
2% of cases of T2D entering spontaneous remission [2], the current clinical paradigm is
that T2D is irreversible. Although current standard clinical care is effective in maintaining
normoglycemia in T2D [3], long-term studies show that intensive glycemic control is
not sufficient in halting T2D progression and decline in pancreatic β-cell function, or in
mitigating the risk of cardiovascular disease [4,5]. Weight loss is the primary approach
for nutritional management of T2D [6,7], and evidence shows that, compared to standard
care, intensive multicomponent lifestyle interventions, including behavior change, physical
activity and dietary energy restriction produce superior weight loss and improvement to
glycemic control [8,9].
Dietary energy restriction approaches for management and treatment of T2D
have largely focused on weight reduction through the use of either low-calorie diets
(LCD) (1200–1500 kcal/day) [10–12], or very low-calorie diets (VLCD) (approximately
400–800 kcal/day) [13–22]. VLCD approaches have shown to be the most effective in
producing rapid weight loss, improvement to pancreatic insulin secretory capacity, and
reduction of hemoglobin A1c (HbA1c) to pre-diabetic and non-diabetic levels, sometimes
within days [13–25]. However, despite this body of evidence [13–25], the long-term efficacy
of VLCD for reversing T2D remains unclear, as many of these studies have been of short
duration (< 12 weeks), did not have T2D remission as a primary endpoint, and varied
greatly in their VLCD protocols, follow up duration, and definitions of T2D remission.
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A recent body of evidence has demonstrated that with VLCD approaches, clinically
defined and sustained (6–24 months) T2D remission can occur [17,20–25], raising the
possibility for a cure of T2D. Evidence from two comprehensive randomized control trials
(RCT) of VLCD [22,25], show that a VLCD intervention led to significant reductions in body
weight and sustained T2D remission in 45–60% of subjects after 12 months, and in 35% of
individuals at 24 months [22,25]. However, data also showed that approximately 30% of
individuals with relatively longer duration T2D (3.8 years since diagnosis) did not achieve
remission despite significant weight loss (i.e., non-responders) [26]. Also, consistent with
numerous VLCD weight loss studies [27], approximately 25% of individuals who achieved
remission from T2D, regained a significant proportion of their lost weight and had their
T2D relapse at 24 months [23,26].
Collectively, these data demonstrate that it remains unclear what the efficacy and
durability of T2D remission is, using VLCD approaches, and, equally important, a better
understanding is needed of which individuals with T2D would most likely respond and
benefit from VLCD approaches for T2D remission.
This narrative review will provide an overview of the studies which share similar
VLCD approaches that specifically sought to measure T2D as a primary endpoint. This
narrative review will also address who is likely to benefit, what the risks are, and how a
VLCD approach compares to other less restrictive hypocaloric diets on remission of T2D.
2. Methods
Our objective was to compile a narrative overview of studies that specifically sought
to examine whether a VLCD and solid food protocol results in durable remission of
T2D. We compiled a list of intervention studies based on the following criteria: (i) used
VLCD protocols based on the definition of a liquid diet formulation of approximately
400–800 kcal/day, (ii) included a solid food reintroduction phase, and (iii) specifically
defined T2D remission in their methodology as a primary endpoint.
A search of the PubMed and EMBASE databases was conducted for English language
original research articles and narrative reviews published from 2000 through January 2021
using the search terms “very-low calorie diet”, “very-low energy diet” and each of the
following terms: “type 2 diabetes” “remission”, and “reversal”. A total of 202 results from
this literature search were returned and then results were further evaluated for relevance
and eligibility for inclusion in this review. Of the 202 articles, five (5) original articles met
our inclusions of caloric range of VLCD, and for specifying remission of T2D as a primary
endpoint. Table 1 summarizes the details and major findings of these 5 studies.
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Table 1. Very low-calorie diet (VLCD) interventions for remission of type 2 diabetes (T2D).
Study
Reference

Lim et al., 2011
[17]

Study
Objective and
Design

Counterpoint
study
-examined
VLCD on
β-cell function
and liver
insulin
sensitivity in
short duration
type 2 diabetes.
Design: Single
arm case
control
intervention
study

Follow Up
Period

2 months

Participants

VLCD
Intervention

24 adults
(35–65 years,
BMI
25–45 kg/m2 )
with type 2
diabetes (T2D)
of <4 years
since diagnosis
(HbA1c 6.5%
to 9.0%). All
antidiabetic
medications
discontinued
at study onset.

8 weeks of a
liquid meal
replacement
formula (46.4%
carbohydrate,
32.5% protein,
and 20.1% fat;
vitamins,
minerals, and
trace elements
(510 kcal/day)
Optifast;
Nestlé
Nutrition,
Croydon, UK),
and 3 daily
portions of
nonstarchy
vegetables for
total daily
caloric intake
of 600 kcal.
Participants
were also
directed to
drink at least
2 L of
calorie-free
beverages/day and
maintain their
typical level of
physical
activity.

Control

9 non-diabetic
controls
matched for
weight, age
and sex.

Counseling
and
Behavioral
Support:

After initial
nutrition
counselling,
ongoing diet
adherence
support was
provided by
telephone.

Measure of
Dietary
Adherence

Adherence
was
determined
using blood
ketone levels

VLCD
Drop-Out
Rate

Definition of
Remission

Mean Weight
Loss (% of
Initial Body
Weight)

Remission
(%)

27.0%

Fasting plasma
glucose levels
(<126 mg/dL),
hepatic insulin
sensitivity
determined by
suppression of
hepatic
glucose
production,
and
normalization
of β-cell
function
(determined
by fasting
insulin
secretion rate)

After 8 weeks
of VLCD: 15%
( ± 1%) of
initial body
weight

After 8 weeks
of VLCD:
100% (24/24)
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Table 1. Cont.
Study
Reference

Steven et al.,
2015 [20], 2016
[21]

Study
Objective and
Design

Counterbalance
study (Counteracting Beta
cell failure by
Long term
Action to
Normalize
Calorie intakE)
-examined
VLCD on short
duration and
long duration
type 2 diabetes.
Design:
Single-arm
intervention
study

Follow Up
Period

2 and 6
months

Participants

VLCD
Intervention

30 adults
(25–80 years,
BMI 27–45
kg/m2 ), T2D
of <4 years
(HbA1c 7.2%)
to >8 years
(HbA1c 8.6%)
since
diagnosis. All
antidiabetic
medications
discontinued
at study onset.

8 weeks of
liquid meal
replacement
formula (43%
carbohydrate,
34% protein
and 19.5% fat;
vitamins,
minerals and
trace elements;
(624 kcal/day);
Optifast;
Nestle
Nutrition,
Croydon, UK),
and up to
240 g of
nonstarchy
vegetables per
day for a total
daily energy of
624–700 kcal.
Followed by a
stepped food
reintroduction
phase with
gradual
reintroduction
of solid food
over 7 days.
Participants
were also
directed to
drink at least
2 L of
calorie-free
beverages/day and
maintain their
typical level of
physical
activity.

Control

None

Counseling
and
Behavioral
Support:

After initial
nutrition
counselling,
ongoing diet
adherence
support
provided
through
telephone,
e-mail, text, or
face-to-face
contact.

Measure of
Dietary
Adherence

Adherence to
liquid diet was
determined
using blood
ketone levels
and to
isocaloric solid
food intakes
from resting
energy
expenditure
measured by
indirect
calorimetry.

VLCD
Drop-Out
Rate

4.0%

Definition of
Remission

Mean Weight
Loss (% of
Initial Body
Weight)

Remission
(%)

Fasting plasma
glucose levels
(<126 mg/dL),
and achieving
nondiabetic
HbA1c levels
(<6.5%)

After 2 months
of refeeding:
14.8% (±0.8%)
and 14.4%
(±0.7%) of
initial body
weight in
short- and
long-T2D
duration
groups
respectively.
After 6 months
of refeeding:
15.8% (±0.5%)
and 13.6%
(±0.7%) of
initial body
weight in
short- and
long-T2D
duration
groups
respectively.

After 2 months
of refeeding:
69% (20/29)
After 6 months
of refeeding:
43% (13/30)
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Table 1. Cont.
Study
Reference

Lean et.al.,
2018 [22], 2019
[23]

Study
Objective and
Design

Diabetes
Remission
Clinical Trial
(DiRECT).
First comprehensive study
of VLCD for
T2D remission
in adults
Design:
Cluster
Randomized
Control Trial

Follow Up
Period

12 and
24 months

Participants

VLCD
Intervention

306 adults
(20–65 years,
BMI
27–45 kg/m2 )
with T2D of
≤6 years since
diagnosis
(HbA1c > 6%).
All
antidiabetic
medications
discontinued
at study onset.

16–20 weeks of
total liquid
meal
replacement
formula (825–
853 kcal/day
(59%
carbohydrate,
13% fat, 26%
protein, 2%
fiber),
followed by a
structured
food
reintroduction
of 2–8 weeks
(50%
carbohydrate,
35% fat, and
15% protein).
All subjects
encourage to
maintain usual
physical
activity during
meal
replacement
stage; and step
counters were
provided
during food
reintroduction
stage with a
target of up to
15, 000 steps
per day.

Control

Standard-care
based on
National
Institute of
Health and
Care
Excellence in
England and
the Scottish
Intercollegiate
Guidelines
Network in
Scotland.

Counseling
and
Behavioral
Support:

CounterweightPlus weight
management
program [28].
Individualized
behavioral
support for
maintaining at
least 15 kg
weight loss,
but with
flexible weight
loss goals
based on
individualized
needs.

Measure of
Dietary
Adherence

Not specified

VLCD
Drop-Out
Rate

25.0%

Definition of
Remission

Mean Weight
Loss (% of
Initial Body
Weight)

Remission
(%)

HbA1c < 6.5%
after at least
2 months off
all antidiabetic
medications
after at least
2 months after
month 12.

After 12
months of
refeeding:
10.0% (±8%)
and 1.0%
(± 3.8%) of
initial body
weight in
the VLCD and
controls arms
respectively.
After
24 months of
refeeding:
7.5% (±6.4%)
and 2.3%
(± 5.2%) of
initial body
weight in
the VLCD and
controls arms
respectively.

After 12
months of
refeeding: 46%
(68/149) and
4% (6/149)
T2D remission
in the VLCD
and control
arms
respectively.
After 24
months of
refeeding: 36%
(53/149) and
3% (5/149)
T2D remission
in the VLCD
and control
arms
respectively.
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Table 1. Cont.
Study
Reference

Umphonsathien,
et. al 2019 [24]

Study
Objective and
Design

Single-arm
intervention
study

Follow Up
Period

14 weeks

Participants

VLCD
Intervention

20 adults
(20–60 years,
BMI of
23–30 kg/m2),
T2D of
<10 years. All
antidiabetic
medications
discontinued
at study onset.

10 weeks of
600 kcal/day
followed by a
step-wise
increased in
kcal/day at
week 10
(800 kcal/
day), week 11,
(1000 kcal/day),
and week 12
(1200 kcal/day),
week 13
(1500 kcal/day).
Participants
were directed
to maintain
their typical
daily lifestyle
throughout the
study.

Control

Counseling
and
Behavioral
Support:

Measure of
Dietary
Adherence

None

After initial
nutrition
counselling,
ongoing diet
adherence
support
provided
through
telephone.

Weekly dietary
recall and
weekly urine
ketone levels
measurement
to measure
dietary
compliance.

VLCD
Drop-Out
Rate

Definition of
Remission

Mean Weight
Loss (% of
Initial Body
Weight)

Remission
(%)

10.0%

Fasting plasma
glucose levels
(<126 mg/dL),
HbA1c levels
(<6.5%), and
no longer
needing
antidiabetic
medications.

After week 14
of refeeding:
13.3% (± 2.2%)
of initial body
weight

After week 14
of refeeding:
79% (15/19).
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Table 1. Cont.
Study
Reference

Taheri, S., et al.
2020 [25]

Study
Objective and
Design

The Diabetes
Intervention
Accentuating
Diet and
Enhancing
Metabolism
(DIADEM-I).
Design:
Open-label,
parallel-group,
randomized
controlled
trial.

Follow Up
Period

12 months

Participants

VLCD
Intervention

158 adults
(18–50 years,
BMI ≥
27 kg/m2 )
with type 2
diabetes
of ≤3 years
since
diagnosis. All
antidiabetic
medications
discontinued
at study onset.

12 weeks of
total liquid
meal
replacement
formula
(800–820 kcal/
day (57%
carbohydrate,
14% fat, 26%
protein, 3%
fiber),
followed by a
structured
food
reintroduction
of 12 weeks.
All subjects
encourage to
maintain usual
physical
activity during
meal
replacement
stage; and step
counters were
provided
during food
reintroduction
stage with a
target of up to
10, 000 steps
per day and to
increase
activity to at
least 150 min
per week.

Control

Counseling
and
Behavioral
Support:

Standard care
based on the
American
Diabetes
Associations
(ADA)
guidelines.

Specialist
Lifestyle
Management
(SLiM) weight
loss program
[29]. A
structured
education and
selfmanagement
weight
management
program.

Measure of
Dietary
Adherence

Not specified

VLCD
Drop-Out
Rate

Definition of
Remission

18.9%

Two levels of
remission. (1)
T2D remission:
HbA1c < 6.5%
and free of
antidiabetic
medications
for at least
3 months. (2)
Normoglycemia:
HbA1c < 5.7%
and no
antidiabetic
medications
for at least
3 months.

Mean Weight
Loss (% of
Initial Body
Weight)

Remission
(%)

After 12
months of
refeeding:
11.9% (±9.4%)
and 3.9.0%
(± 5.2%) of
initial body
weight in
the VLCD and
controls arms
respectively.

After 12
months of
refeeding: (1)
T2D remission:
60% (42/70)
and 12% (9/77)
in VLCD and
controls arms
respectively.
(2) Normoglycemia: 33%
(23/70) and 4%
(3/77) in
VLCD and
control arms
respectively.
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3. Results and Discussion
3.1. Definition and Safety of Liquid Very Low-Calorie Diets (VLCD)
Historically, use of VLCDs for treatment of obesity gained considerable attention in
the 1970s for their effectiveness in producing marked and rapid weight loss, often with
body weight reductions of 20–30% in 12–16 weeks [30,31]. A VLCD protocol typically
involves the replacement of all food with a medical grade liquid diet formulation that
provides approximately 400–800 kcal/day for 12 to 16 weeks, followed by a structured
solid food reintroduction phase with kcal/day tailored for weight loss maintenance [30].
Most VLCD liquid formulas consisted of approximately 50–60% of kcal from carbohydrate
(maltodextrins and sucrose) to prevent ketosis, sufficient levels of essential fatty acids
to meet the recommended dietary allowances, and high-biological-value protein (i.e.,
whey isolate) at 1.2–1.5 g/kg body weight to prevent loss of lean muscle mass during
rapid weight loss [30]. Liquid VLCD formulas typically contained very little fiber and
are sweetened with artificial sweeteners such as aspartame and sucralose [30]. Although
VLCD formulas typically contain sufficient vitamins and minerals to meet the dietary
requirements of adults, intake of a vitamin and mineral supplement is suggested [30], as
an underestimation of micronutrient needs for obese adults, and those using VLCD has
been reported [32,33].
Under medical supervision a VLCD is generally considered safe [30,31], but a number
of side effects, particularly in the early stages of liquid diet administration, can occur,
including fatigue, constipation, and diarrhea [30,31]. More serious adverse events are infrequent and include hyperuricemia, gout, and cardiac complications [30,31]. Due to lower fat
intakes, concerns about development of gallstones with low calorie diets, including VLCD
have been reported [30,34–36]. Replacing carbohydrate and protein with additional fat in
liquid diet formulas could potentially promote gallbladder emptying which can reduce
the risk of gallstone formation [30]. As unsupervised use of VLCDs can result in serious
medical complications, intensive and comprehensive medical monitoring by a physician in
conjunction with a registered dietitian (RD) is highly recommended [30,31].
Risk for hypoglycemia can increase with combined use oral hypoglycemic agents, in
particular sulfonylureas (i.e., gliclazide, glimepiride), or exogenous insulin, with a VLCD
protocol [31]. Therefore, close medical supervision and dose adjustments or discontinuation
of oral hypoglycemic agents with a VLCD is recommended, particularly during the total
food replacement phase [31]. Moreover, individuals should be trained in the use of home
blood glucose monitoring during any adjustment period of antidiabetic medications [31].
Medications for hypertension are also often decreased or discontinued at the onset of a
VLCD protocol, but should be re-introduced if hypertension is elevated or returns [31].
Also, with the danger of hypotension and electrolyte disturbances, discontinuation of
diuretics should also be considered [31].
3.2. Definition of Type 2 Diabetes (T2D) Remission
The specific use of VLCD as a protocol for T2D remission is recent and relatively unexplored, as the majority of VLCD studies to date have focused on weight loss [27,30,37,38].
Although there have been numerous studies demonstrating various degrees of improvements to glycemic control with VLCD [13–16,18,19], the majority of these have not specifically defined the parameters of T2D remission as a primary endpoint.
In response to growing evidence of T2D remission after bariatric obesity surgery
(reviewed in [39]), in 2009, Buse et al. [40] provided the following working definition of
T2D remission: “Remission is defined as achieving glycemia below the diabetic range
in the absence of active pharmacologic (antihyperglycemic medications, immunosuppressive medications) or surgical (ongoing procedures such as repeated replacements of
endoluminal devices) therapy. Remission can be characterized as partial or complete: (1)
partial remission is sub-diabetic hyperglycemia (A1c not diagnostic of diabetes [<6.5%,
<48 mmol/mol], fasting glucose 100 to 125 mg/dL) and (2) complete remission is a return to
“normal,” measures of glucose metabolism (A1c in the normal range [<5.7%, 39 mmol/mol],
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fasting glucose <100 mg/dL). Partial or complete remission requires at least 12 months of
the absence of active pharmacologic therapy or ongoing procedures to be characterized in
a remissive state.”
A recent meta-analyis shows that the large degree of heterogeneity in how T2D
remission is defined remains a major barrier to arriving at consensus on the efficacy of
VLCD and T2D remission [41]. With the exception of Lim et al. [17], all the studies included
in this narrative review use components of the Buse et. al. [40] definition of T2D remission.
3.3. Effect of Very Low-Calorie Diets on Remission of T2D
We summarized five (5) VLCD studies that specifically examined VLCD for T2D
remission, and defined T2D remission parameters in their methods [17,20–25] (Table 1).
The Counterpoint study (Counteracting Pancreatic Inhibition by Triglyceride) Lim et al. [17],
was among the first studies to comprehensively explore T2D remission with VLCD. More
specifically, it sought to examine the relationship between excess pancreatic lipid and
impaired insulin responses in the reversal of T2D, and to test the twin cycle hypothesis for
the onset of T2D (reviewed in [42]). The Twin Cycle hypothesis purports that in obesity and
pre-diabetes, fatty liver and hepatic overproduction of triglyceride-rich very-low density
lipoprotein (VLDL) has a spillover effect, leading to ectopic pancreatic fat accumulation,
impaired β-cell function and onset of T2D [42]. The Counterpoint study used an 8-week
VLCD protocol of 600 kcal/day (25% of energy requirement) in 11 obese subjects with T2D
who had relatively short-duration disease of less than 4 years since diagnosis [17].
All metabolic parameters were compared to baseline recruitment values and against
those of age and sex-matched non-diabetic controls [17]. They reported that, after 7 days
of the VLCD, participants had reductions in fasting plasma glucose (FPG) to non-diabetic
levels (<100 mg/dL), as well as significant reductions in fasting plasma insulin (p < 0.05),
and triglyceride (p < 0.01). The normalization of FPG to non-diabetic levels after just
7 days occurred with a modest weight loss of approximately 4% of initial body weight,
but a 30% decrease in ectopic pancreatic and hepatic triglyceride [17]. At the completion
of 8-weeks, the VLCD intervention resulted in a body weight reduction of 15 kg, and all
subjects maintained the 30% reductions in intrahepatic and pancreatic lipid levels, with 73%
of subjects maintaining non-diabetic FPG levels [17]. The Counterpoint study provided
proof of concept that with VLCD normalization of glycemic control in T2D is possible,
and evidence that short-term VLCD promotes marked improvement in hepatic insulin
resistance and normalization of β-cell function [17].
Given the positive results of the Counterpoint study in participants with relatively
new onset of T2D [17], a larger and longer follow-up study by Steven et al. [21] sought
to examine the effects VLCD in subjects with relatively longer T2D disease duration.
Coined the Counterbalance study (Counteracting BetA cell failure by Long term Action
to Normalize Calorie intakE), this study expanded the VLCD protocol from Lim et al. in
three phases: 8 weeks of VLCD liquid formula (624–700 kcal/day), followed by 2 weeks
of an isocaloric solid food diet, and then by a structured and individualized 6-month
weight maintenance program. Subjects that achieved non-diabetic T2D remission were
categorized as “responders”, defined by achievement of a FPG of <125 mg/dL and HbA1c
levels of <6.5% (<48 mmol/mol) at the 2-month and 6-month follow-up periods. They
found, similar to Lim et al. [17], that in some individuals FPG levels were rapidly reduced
to non-diabetic levels within 7 days after the onset of the VLCD [21]. After 8-weeks on
the VLCD, mean weight loss was approximately 15% of baseline body weight among both
responders and non-responders, which then remained unchanged in both groups over the
6- month duration of the study. However, after 8 weeks of VLCD, 87% of subjects with
relatively shorter T2D duration (<4 years since diagnosis) had non-diabetic FPG levels,
whereas just 50% of the long- duration T2D group (8–23 years since diagnosis) achieved
non-diabetic FPG. At a 6-month follow up, during the weight maintenance phase, 40% of
the participants in the VLCD intervention arm were classified as responders and in T2D
remission [21]. Compared to non-responders, 60% of responders had relatively shorter
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duration disease of <4 years at baseline, lower FPG, HbA1c, and higher first phase insulin
responses [21]. Also, consistent with findings in Lim et al. [17], improvements to β-cell
function in responders occurred with concomitant reduction in pancreatic fat levels [21].
The 10-year Q-RISK score, a metric used to assess cardiovascular disease (CVD) risk [43],
was reduced from 23% to 7% in responders from the Counterbalance study, which is
consistent with a large body of data demonstrating significant reductions in CVD with
weight loss and glycemic control in T2D [44,45].
Similarly, a small prospective VLCD study by Umphonsathien et al. [24], specifically
examined T2D remission in 19 overweight adults (mean body mass index [BMI] 27.7), with
an average T2D duration of 2 years (range 0.4–8 years). Subjects were administered a VLCD
of 600 kcal/day for 10 weeks, followed by a 4-week gradual solid food reintroduction
phase, and an increase in energy intake up to 1500 kcal/day. Dietary compliance was
measured using a daily food record and urine ketone levels. They defined T2D remission
as FPG level <126 mg/dL, HbA1c <6.5% (<48 mmol/mol), and the discontinuation of all
antidiabetic medications. Dietary compliance was reported at 90%, and they reported that
at weeks 4, 8 and 12 of the re-feeding phase, approximately 40%, 75% and 70% of subjects
were in T2D remission, respectively [24]. Over 12 weeks, those who achieved remission had
a mean weight loss of 9.5 kg or 12% of initial body weight. This small study found, similar
to the Counterpoint and Counterbalance studies [17,20,21], that improvement in glycemic
control was apparent in the first 7 days of onset of the VLCD and that duration of T2D
was a predictor of remission (mean duration of 2 years vs. 6 years in non-responders) [24].
While it would have been informative, rates of remission were not reported after the refeeding period. Although this study, along with Counterpoint and Counterbalance studies,
provides proof of concept that VLCD can result in T2D remission with a high response
rate, these studies lack the appropriate controls, and had relatively short follow-up of
2–6 months.
The Diabetes Remission Clinical Trial (DiRECT) sought to address these limitations
with a rigorous and comprehensive study of a VLCD approach for T2D remission that
spanned 24 months [22,23]. DiRECT recruited 306 overweight and obese adults aged 20–65
with a BMI range of 27–45 kg/m, diagnosed with T2D within the past 6 years [22]. Exclusion
criteria included diagnosis of very advanced T2D, defined as requiring exogenous insulin
or with an HbA1c of 12% (108 mmol/mol) or greater [22]. All subjects were then cluster
randomized to either a VLCD protocol, or a standard diabetes care intervention [22]. The
VLCD intervention arm involved 3 phases: 1) Total diet replacement phase: a daily liquid
formula diet replacement providing 825–853 kcal/day for 3–5 months (duration based on
individualized weight loss goals); followed by 2) Food reintroduction phase: a stepped
food reintroduction and increase in daily kcal for 6–8 weeks, adjusting individualized
caloric intake for maintaining weight loss; and 3) Weight loss maintenance phase: a
24-month, multi-pronged, individualized medical and behavioral support model called
the Counterweight-Plus program delivered either by a nurse or registered dietician for
long-term weight maintenance [22,23]. The Counterweight-Plus program has been shown
to be effective in real-life primary care settings in the community and, because it can be
administered either by dietitians or a nurse, it reduced cost VLCD treatment to less than
half of the average cost for treating an individual with T2D in the U.K. [28]. Remission
from T2D was defined as HbA1c < 6.5% (<48 mmol/mol) after at least 2 months without
the need for antidiabetic medications. The attrition rate for the DiRECT intervention group
was 25% at 12 months [22], which is superior to the 25–50% dropout rates in the first 3 to
6 months of prior VLCD studies [27,46,47]. Results from the primary outcomes of T2D
remission and weight loss were reported based on an intent-to-treat model [22,23].
At 12 months, within the VLCD intervention arm, 46% of participants achieved
remission of T2D, mean weight loss was 10 kg, and 25% lost over 15 kg of body weight [22].
Remission rates and weight loss in the standard care arm at 12 months were 4% and 0%
respectively [22]. Almost 74% of subjects in the VLCD intervention arm no longer needed
antidiabetic medications compared to 18% in the standard care arm at month 12 of the
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weight maintenance phase [22]. Subjects in the VLCD intervention arm also had marked
reductions in blood pressure, with 48% of participants no longer requiring the use of
antihypertensive drugs, compared to no reductions in antihypertensive drug use in the
standard care arm [22]. A 24 month follow up showed that 35.6% of subjects in the VLCD
intervention arm remained in T2D remission, and among those who achieved remission,
70% maintained a weight reduction of over 15 kg [23]. Improvement in quality of life and
general well-being were higher in subjects in the VLCD intervention than those in the
standard care arm [23].
The Diabetes Intervention Accentuating Diet and Enhancing Metabolism (DIADEM-I)
trial is another RCT in similar size and scope to the DiRECT that also specifically sought to
examine T2D remission as a primary endpoint [25]. DIADEM-I recruited 147 overweight
adults aged 18–50 with a BMI 27 kg/m2 or greater, and a mean T2D duration of <3 years
(mean of 21.2 months) [25]. DIADEM-I defined T2D remission using a similar parameter as
DiRECT, of HbA1c < 6.5% (<48 mmol/mol), and being free of antidiabetic medications for
at least 3 months [25]. However, unlike DiRECT, DIADEM-I also included a more rigorous
level of remission termed “normoglycemia” defined as HbA1c <5.7% (<39 mmol/mol),
with no antidiabetic medications for at least 3 months [25]. All participants stopped use
of antidiabetic medications, and were then randomized to receive either a supervised
intervention of 12 weeks of a either a total diet replacement of a VLCD liquid formula of
800–820 kcal/day, followed by a structured 12-week food reintroduction phase (n = 70), or
standard care (n = 77), based on American Diabetes Associations (ADA) guidelines [48].
Subjects in the VLCD arm also received behavioral support using a multi-component
approach called the Specialist Lifestyle Management (SLiM) weight loss program, that was
reported to be successful in facilitating weight loss in obesity [29]. The follow up period
was 12 months from baseline. Consistent with the DiRECT [22], subjects in the VLCD
intervention arm of DIADEM-I had a mean weight reduction of 11.98 kg at month 12, with
15% of subjects achieving a weight loss of greater than 15% of body weight, compared to
3.98 kg of weight loss in the control arm [25]. T2D remission and normoglycemia occurred
in 61% and 33% of participants respectively in the VLCD intervention arm, and 12% and
4% of participants in the control arm. Similar to the DiRECT [22], the drop-out rate in the
VLCD arm was 18.9%, (15/79), and in the control arm 12.6% (10/77) [25].
3.4. Comparison between a Very Low-Calorie Diet and a Low-Calorie Diet for T2D Remission
The DiRECT and the DIADEM-I are the only large-scale RCTs of VLCD to examine
T2D remission as a primary endpoint. However, it is appropriate to compare their findings
to those of the Look AHEAD study [10,49], the largest-RCT to examine the potential of
an intensive lifestyle intervention (ILI) of diet, exercise and behavioral support to achieve
and maintain long-term weight loss among obese individuals with T2D [10,49]. LookAHEAD randomized 2241 participants to an ILI of a low-calorie diet of 1200–1500 kcal/day,
physical activity and intensive behavioral support [10,49]. The ILI group was compared
to individuals in a standard care of diabetes support and education intervention (DSE).
At the 4-year outcomes assessment, approximately 50% of the ILI group maintained the
loss of 5% of their baseline body weight, and 27% lost and maintained 10% of their baseline body weight [10,49]. Although T2D remission was not a primary endpoint, using a
definition of FPG of <126 mg/dL, HbA1c of <6.5% (<48 mmol/mol), without requiring
any antihyperglycemic medication, post-hoc analysis in the Look AHEAD reported that
11.5% participants in the ILI group had partial or complete remission of T2D by 12 months,
and 9.2% had T2D remission at 24 months, compared to 2% remission in the standard care
group [10]. Also, individuals that achieved T2D remission in the ILI group, maintained
6.3% of their lost weight, compared to 0.9% weight loss maintenance in the standard care
group [10,49]. A follow-up showed a decline in T2D remission rates, with 7.5% of ILI participants in remission after 4 years [50]. Compared to the LookAHEAD, mean weight loss
(10 kg vs. 8.6 kg) was similar, but T2D remission rates at 12 months (46% vs. 9.2%), were
superior in the DiRECT [10,22]. It is unclear why, despite having less than 15% difference
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in the mean weight loss reductions after 12 months, that the differences in T2D remission
rate in the DiRECT study was markedly greater (>130%) than that of LookAHEAD.
A study by Sarathi et. al. [51] sought to examine T2D remission, but with more
moderate calorie restriction of 1500 kcal/day than those typical of VLCD. They recruited
28 adults (mean 24 years of age) with newly diagnosed T2D (<12 months), who were then
counseled to consume 1500 kcal/day using solid foods and to undertake daily brisk walking
for 1 hour per day with follow-ups at 3, 12 and 24 months. After 3, 12 and 24 months,
remission, defined as FPG of <100 mg/dL and HbA1c of <5.7% (< 39 mmol/mol), was
reported in 53.1%, 50% and 46.9% of subjects [51]. Mean weight loss at 3, 12 and 24 months
was 4.97 kg, 6.56 kg and 7.66 kg, respectively. The 24-month mean was 8.2% of initial body
weight, which is similar to the 7.6% weight reduction reported in the VLCD arm in the
DiRECT at 24 months [23].
Lastly, a small study (n = 8), by Petersen at al. [52], demonstrated in obese subjects
with T2D, that euglycemia and improved insulin sensitivity can be achieved with a modest
energy restriction of ~1200 kcal/day for 7 weeks [50]. The authors noted that normalization
of T2D parameters occurred in all 8 individuals, and with a body weight reduction of
8 kg, but an 80% reduction of intra-hepatic lipids [52]. These data suggest that T2D
remission, albeit at lower rates than observed with VLCD [17,20–24], is possible with even
modest calorie restriction and exercise. This opens the possibility that individuals who
struggle with the more aggressive calorie restriction of VLCD have alternatives for T2D
remission approaches.
3.5. Characteristics of Good Candidates for Use of VLCD for T2D Remission
Although weight loss was among the strongest predictors of T2D remission [22,53],
evidence from the Counterbalance and DiRECT studies demonstrated that approximately
30–56% of individuals that lost appreciable body weight (more than 15 kg) still did not
achieve T2D remission (non-responders) [21,26], demonstrating that weight loss in itself is not sufficient for reversal of T2D. A post-hoc analysis in a subset of the DiRECT
cohort [54], found that non-responders had significantly longer duration of T2D since
diagnosis (3.8 vs. 2.7 years (responders), p = 0.02). It was also reported that compared
to responders, non-responders at 24 months had higher pancreatic fat, and poorer β-cell
function, with approximately 50% lower first phase insulin secretory response [54]. No
baseline demographic or metabolic parameters, including age, sex, BMI, liver or pancreatic
fat content, differed between non-responders and responders [54]. Similarly, the Counterbalance study [21] found a significant gap in T2D duration between VLCD responders and
non-responders (3.8 vs. 9.8 years), and also found age to be a factor, with non-responders
being ~8 years older than responders (52 vs. 59.9 years). Furthermore, the DIADEM-I
study [25], which recruited adults with relatively short duration T2D of 3 years or less,
reported a higher percentage of remission at 12 months (60%) compared to the DiRECT
(46%), which recruited adults with a mean T2D duration of 6 years or less [22], supporting
a possible role of disease duration in predicting T2D remission. The LookAHEAD study
also reported that T2D remission was highest among subjects with the shortest length of
T2D (≤2 yrs.) [10]. Furthermore, several bariatric obesity surgery studies have shown that
baseline pancreatic β-cell function is a strong predictor of T2D remission [55–57].
Together these data suggest that only individuals with a relatively shorter duration
disease, and a critical mass of pancreatic β-cells and/or β-cell function, should be candidates for hypocaloric T2D remission protocols. However, surprisingly, post-hoc analysis of
the original full DiRECT cohort found that weight loss, not T2D duration, was the strongest
predictor of T2D remission [53]. Also, though the DIADEM-I reported higher rates of
remission at 12 months compared to the DiRECT, the VLCD participants in the DIADEM-I
were appreciably younger than subjects in DiRECT VLCD arm (41.9 vs. 52.9 yrs.). Participants that achieved T2D remission in the Counterbalance study were also younger than
participants that did not (52.0 vs. 59.9 yrs.) [21], together suggesting that age itself may be
a key factor in determining an individual’s potential for T2D remission.
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A recent study reported that higher levels of the orexigenic hormone ghrelin during
the liquid diet phase of VLCD is a predictor of weight regain [58], suggesting that preenrollment ghrelin levels may be an effective screening tool. Evidence suggesting that
disease duration and β-cell function are predictors of T2D remission is consistent with
the pathophysiology of T2D, in which the onset of pancreatic β-cell loss and secretory
insufficiency represent a key clinical transition from insulin resistance to T2D [59]. Nevertheless, until there is a better understanding of the relationship between disease duration,
pancreatic β-cell function, and potential for T2D remission, it is currently not possible to
screen candidates most likely to succeed in achieving T2D remission. This is particularly
important knowing the challenges, potential health risks and costs that are associated with
undertaking a medically supervised VLCD protocol [31].
3.6. Degree of Weight Loss Necessary for T2D Remission
The current arguments against the use of a VLCD for weight loss are based on a body
of data demonstrating that VLCD approaches are only effective in producing rapid weight
loss in the short-term (<12 months), and that after the reintroduction of solid food in the
long-term (≥24 months), marked weight regain is typical [27,31,45]. Data from a number
of meta-analyses of VLCDs are in agreement that in the long-term (1–5 years of follow
up), most individuals fail to maintain the 15–20% weight reductions that are typical of
VLCDs [27,28,45]. However, data show that various degrees of T2D remission can occur
across a wide range of weight loss, sometimes before any appreciable reduction in body
weight occurs [10,15,18,20,23]. For example, a weight loss VLCD study by Henry et. al. [15]
of 30 obese adults (mean BMI >35) with T2D, reported that within just 10 days of the
VLCD, 87% of intervention subjects (26/30) showed significant reductions (p < 0.001) in
FPG, insulin levels, and hepatic glucose output (HGO), while losing only ~4% of their
initial body weight [15]. In the DiRECT, at 24 months T2D remission in the VLCD arm was
reported in 5% of individuals that lost as little as 5 kg of weight, almost 30% of individuals
that lost 5–10 kg of weight, and almost 60% of participants that lost 10–15 kg of weight,
or 10–15% of their initial body weight [23]. No data on remission within ranges of weight
loss was reported in the DIADEM-I study [25]. Evidence that more modest weight loss
and T2D remission was also reported in the LookAHEAD study [10], which showed a
significant (p < 0.01) association between T2D remission across all tertiles of weight loss in
the ILI group [10].
Together, these data show that with VLCD, short-term onset of T2D remission can
occur with even negligible weight loss, and for some individuals, modest reductions in
body weight of 10–15% that have been documented in numerous VLCD studies [27,38],
are sufficient for maintaining T2D remission in the long-term. These data also suggest that,
unlike typical anti-obesity approaches that emphasize maximum weight loss [27,46], future
VLCD practices for T2D remission should favor highly flexible and tailor-made weight loss
targets that consider individual responses.
3.7. Comparison of VLCD Approaches with Bariatric Surgery for T2D Remission
A body of data shows that morbidly obese subjects with T2D that undergo bariatric
surgery can achieve, sometimes within days, non-diabetic FPG glucose levels [39]. A number of side-by side studies comparing the magnitude of short-term normalization of T2D
parameters between VLCD and gastric bypass surgery, show that - both VLCD and bariatric
surgery produce similar improvements to FPG and HbA1c [60–64], and marked calorie
restriction itself, not weight loss, is a key contributor to T2D remission in the short- term
(<4 weeks). To date, just one study the examined the side-by-side improvements to T2D
glycemic control between VLCD and the most common bariatric surgery, Roux-en-Y Gastric Bypass (RYGB), in the medium-term (3 months) [65]. That study showed that after
3 months, FPG, HbA1c and HOMA-IR were similarly reduced by VLCD and RYGB, though
weight loss was superior with RYGB [65].
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Although long-term T2D remission with bariatric surgery varies greatly depending on
the type of surgery, and other factors such as severity of baseline T2D [39], remission rates
between 30–63% over a range of 1–5 year follow ups have been reported with bariatric
surgery [39,66,67]. For example, a large meta-analysis by Arterburn et al. [66], showed that
at 1, 3, and 5 years after RYGB bariatric surgery, 37.1%, 63.3%, and 68.2% of individuals
achieved complete T2D remission (defined as discontinuation of T2D medication, FPG <100
and/or HbA1c levels <6.5% (<47.5 mmol/mol) for ≥ 90 days [66]. Complete T2D remission
after 2 years was reported in approximately 55% of subjects [66]. Another meta-analysis
found that for all forms of bariatric surgeries (i.e. gastric bypass, sleeve gastrectomy, and
gastric banding), complete T2D remission was achieved by 66.6% of subjects between
2–5 years post-operatively [67].
Using a similar definition of T2D remission, data from the DiRECT shows that after 1
and 2 years, remission was reported in 45.6% and 35.6% of subjects [23]. These data suggest
that VLCD and bariatric surgery produce similar reductions to T2D parameters in the shortto medium-term, but in the long-term (>2 years), remission rates are superior with bariatric
surgery. However, higher T2D remission was reported at 1 year in DIADEM-I compared to
those reported by Arterburn et al. (60% vs. 37.1%) [66]. Subjects in the DIADEM-I were
on average younger (41.9 vs. 49.6 years), and with shorter duration T2D (<3 vs. 4.5 years)
than the bariatric surgery subjects examined by Arterburn et al. [66], suggesting that for
shorter duration T2D, VLCD may be as good or better than bariatric surgery in producing
T2D remission. However only with longer follow up studies (> 2 years) of VLCD on T2D
remission can a reliable comparison be made between these two T2D treatment approaches.
Disadvantages of bariatric surgery include the risk of surgical and post-surgical
complications, such as wound infection and thromboembolism [68,69], and significant
financial burden, with a mean cost of $14,389 in the U.S. [70]. Although some adverse health
risks are associated with use of VLCD [30] (see above), data from the DiRECT suggest
that VLCD can be administered with few health risks [22]. Compared to previous VLCD
studies [28,29,32,33], the DiRECT study reported a smaller number of adverse events,
including gallstones, which were 7%, (11/157) in the VLCD arm, and 13% (19/149) in
the standard care arm [22]. No differences in adverse events between VLCD and control
arms was reported in the DIADEM-I [25]. Therefore, given the evidence that VLCD
approaches are effective in achieving clinically meaningful T2D remission [22,23,25], and
are comparably safer than invasive surgery, a VLCD could represent a viable alternative to
bariatric surgery for individuals with the goal of achieving T2D remission.
4. Summary and Conclusions
In this review we examine the findings from five (5) studies that specifically sought to
investigate the effect of VLCD on remission of T2D [17,20–25]. A limitation of this narrative
review is the absence of a quantitative treatment of this topic, i.e., meta-analysis. However,
within the scope of the five (5) intervention trials reviewed here, including a critical analysis
of the DiRECT cohort, the largest RCT to examine VLCD in T2D, data show that a VLCD
approach results T2D remission in approximately 50% of subjects after 12 months, and
30% of subjects after 24 months [22,23,25]. Data from DiRECT and a number of these
VLCD studies also show that subjects with a relatively shorter duration of T2D and better
pancreatic β-cell function, are more likely to achieve T2D remission [10,15,21,54].
However, these findings provide little by way of developing specific and effective
screening criteria for VLCD T2D remission protocol candidates, as there is a large degree of heterogeneity in the definition of short and longer duration T2D across these
studies [21,23,54]. As it stands, evidence suggests that only subjects with a relatively recent
T2D diagnosis may benefit from VLCD or other energy restriction approaches to elicit T2D
remission. Nevertheless, there is a need for more specific biomarkers and screening methods
in order to determine those most likely to benefit from a VLCD T2D remission approach.
Currently, VLCDs are typically reserved for individuals who are severely and morbidly obese (BMI >30–35), who are resistant to standard treatments, and require medically
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justified rapid weight loss, such as prior to orthopedic surgery or organ transplant [30,71].
A VLCD is also commonly used 2–3 weeks prior to bariatric surgery to reduce visceral and
liver fat mass, thereby minimizing peri- and post-surgical complications [72]. Nevertheless,
due to cost, and questions of long-term efficacy and potential health risks, including fatigue,
diarrhea, and gall stones [30,34,35], VLCD approaches remain outside of standards of clinical care for the treatment of obesity and T2D [31]. The recent endorsement by the American
Diabetes Association for short-term usage of VLCDs for improving glycemic control is
noteworthy [7], and evidence that VLCD is effective in reversing T2D in adolescents [73],
suggests that more medical bodies may reconsider their positions on the use of VLCD in
the treatment of T2D. As such, in the U.K., the National Health Service (NHS), recently announced the use of VLCD for remission treatment of T2D in some regional locations based
on the DiRECT Counterweight program [28,74]. The NHS- sponsored implementation of
VLCD protocols for treatment of T2D will be an invaluable test balloon, not only for the efficacy of VLCDs, but also on the primary care-based model for delivering an intensive diet
and lifestyle approach for T2D remission. Such approaches hold the potential to provide a
viable dietary, non-pharmacological approach for reversing T2D, as well as to mitigate the
risk for T2D-related comorbidities, including heart disease, renal disease, and retinopathy.
Although these studies have provided insight into the real potential for reversibility of
T2D with weight loss after extreme caloric restriction, they are limited by their lack of
long-term follow-up. A critical question also not addressed in these studies, is whether
self-directed and long-term adherence to VLCD protocols are feasible, effective, and safe.
There are limited data supporting long term maintenance of weight loss and subsequent
glycemic improvements in response to VLCDs. Although evidence suggests that with
intensive behavioral support, durability of weight loss with VLCD is improved [27,75–77],
successful long-term adherence to these dietary approaches will continue to be challenging
among individuals who lack optimal support for sustained behavior change. Until further
research on long-term sustainability of VLCD is conducted, approaches to meal planning
should be individualized, whereby physicians and RDs provide one-on-one guidance and
support along the way.
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